The biggest corporate spender in biotech isn’t the investment arm of a well-known Big Pharma. Rather, Google parent Alphabet’s GV earns that title, having participated in deals worth a cumulative $5.23 billion since the beginning of 2025.
Biopharma has collected $54.5 billion across 959 rounds globally since the start of 2025 through 2026’s third quarter, with U.S. companies attracting $37.2 billion—about 68% of the total funding.
